Combination Drug Therapy More Effective for Kala-azar Treatment

Combination treatments for Kala-azar (visceral leishmaniasis) have proved to be more effective and safe than the standard treatment, says a new study in the online edition of The Lancet.

According to the study combination treatment for visceral leishmaniasis reduces the duration of therapy, thereby encouraging adherence and reducing the emergence of drug-resistant parasites.

Leishmaniasis (Kala-Azar) – Symptoms, Signs, Diagnosis, Treatment & Prevention
Leishmaniasis (Kala-azar) refers to the spectrum of infectious disease produced by species of the Leishmania parasite. The parasites spread by the bite of infected sand flies.

In the study that was conducted between June 2008 and July 2009, researchers studied 630 patients and compared standard treatment with amphotericin-b infusion with the 3 drug combinations in two different hospitals in Bihar. The results showed that combination therapy proved to be more effective.

Source-Medindia

Tata Group Pharma Firm Tie-up With Geneva-based DNDi for the Research of Kala-azar
The Advinus Therapeutics (P) Ltd, a Tata Group pharmaceutical company, tie-up with the Geneva-based Drugs for Neglected Diseases initiative (DNDi) for research of therapies for Kala-azar

US-based Pharma Launches Phase-4 Treatment for Kala-azar in India
(iOWH), the US-based non-profit pharmaceutical company announced Phase 4 pharmacovigilance and access program of Paromomycin IM Injection for the treatment of visceral leishmaniasis

One Third of Nepalese Facing Risk of Kala-azar
A third of Nepal's population faces risk of suffering from Kala-azar - a chronic and potentially fatal parasitic disease of the viscera with figures going up from 5,616,489 in 2006